Drug
Zalcitabine clinical trials
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
How studies write it
Studies that test it under each name
Name
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
- Phase 3
- 1
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Hoffmann-La Roche (7) · National Institute of Allergy and Infectious Diseases (NIAID) (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Zalcitabine is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of Dideoxycytidine in HIV-Infected PatientsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00000997Written as Zalcitabine
- A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000704Written as Zalcitabine
- A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZTCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000653Written as Zalcitabine
- Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddCCompletedPhase 2Hoffmann-La RocheNCT00001040Written as Zalcitabine
- An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492CompletedPhase 2Hoffmann-La RocheNCT00002265Written as Zalcitabine
- A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous TreatmentCompletedPhase 3Hoffmann-La RocheNCT00002334Written as Zalcitabine
- An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical StudiesCompletedNot applicableHoffmann-La RocheNCT00002118Written as Zalcitabine
- A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)CompletedNot applicableHoffmann-La RocheNCT00002279Written as Zalcitabine
- Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.CompletedNot applicableHoffmann-La RocheNCT00002256Written as Zalcitabine
- A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take ZidovudineCompletedPhase 2Hoffmann-La RocheNCT00002333Written as Zalcitabine
Codes
What other systems call Zalcitabine · ClinicalTrials.gg INT008510
- MeSH (NLM) D016047ZalcitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6L3XT8CB3IZALCITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 3363Confirmed FDA, Wikidata
- Wikidata Q2344582zalcitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C430ZalcitabineOne source FDA
- DrugBank DB00943One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D016047 | Zalcitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6L3XT8CB3I | ZALCITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3363 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2344582 | zalcitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C430 | Zalcitabine | One source FDA |
| DrugBank | DB00943 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.